以腸道菌群為靶點(diǎn)治療原發(fā)性膽汁性膽管炎的臨床應(yīng)用

摘要：原發(fā)性膽汁性膽管炎（PBC）是一種以膽管上皮細(xì)胞為特征性靶標(biāo)的進(jìn)行性膽汁淤積性肝病。“疾病腸治”是近年的研究熱點(diǎn)。未來(lái)或可通過(guò)益生菌改善腸道菌群豐度及分布，重塑腸道微環(huán)境，進(jìn)而干預(yù)PBC疾病進(jìn)展。本文從腸道菌群角度及益生菌的臨床應(yīng)用方面進(jìn)行綜述，為PBC尋找新的治療策略提供思路。

關(guān)鍵詞：肝硬化， 膽汁性； 胃腸道微生物組； 治療學(xué)

基金項(xiàng)目：內(nèi)蒙古自治區(qū)衛(wèi)生健康科技計(jì)劃項(xiàng)目（202201282）;  內(nèi)蒙古自治區(qū)自然科學(xué)基金項(xiàng)目（2022LHMS08019）

Treatment of primary biliary cholangitis by targeting intestinal flora

MA Minghan， LIU Yanqi. （Department of Gastroenterology， The Affiliated Hospital of Inner Mongolia Medical University， Huhehot 010050， China）

Corresponding author：LIU Yanqi， 109307436@qq.com （ORCID：0000-0002-4735-6712）

Abstract：Primary biliary cholangitis （PBC） is a progressive cholestatic liver disease targeting biliary epithelial cells， and the concept of “treating diseases by intervening with the gut” has become a research hotspot in recent years. In the future， probiotics may be used to improve the abundance and distribution of intestinal flora， reshape the intestinal microenvironment， and intervene against the progression of PBC. This article reviews the gut microbiota and the clinical application of probiotics， so as to provide ideas for finding new treatment strategies for PBC.

Key words：Liver Cirrhosis， Biliary; Gastrointestinal Microbiome; Therapeutics

Research funding：Health  Science and Technology Project of Inner Mongolia（202201282）; Natural Science Foundation of the Inner Mongolia（2022LHMS08019）

原發(fā)性膽汁性膽管炎（PBC）是一種以肝內(nèi)膽管上皮細(xì)胞（biliary epithelia cell，BEC）為特征性靶標(biāo)的具有器官特異性的自身免疫相關(guān)肝病。（剩余11622字）